Summary
United States Patent 8,431,597 (the ‘597 patent), granted on April 30, 2013, covers a novel pharmaceutical composition and method involving a specific class of compounds. Its claims primarily focus on the chemical structure, pharmaceutical formulations, and therapeutic methods. The patent landscape indicates a strategic position within the neurodegenerative disease treatment space, especially in relation to compounds targeting specific receptors or pathways. The patent’s scope encompasses structural, method-of-use, and formulation claims, positioning it broadly within the applicable technologies.
What Is the Scope of the ‘597 Patent’s Claims?
Structural Claims
The core claims of the patent protect specific chemical compounds. These compounds are characterized by a particular core structure with functional groups that define the scope of protected molecules. The claims include variations and substitutions at certain positions, which widen the scope to encompass a family of related compounds.
Method-of-Use Claims
Key claims cover therapeutic methods employing these compounds to treat neurological and psychological disorders, such as Alzheimer’s disease, Parkinson’s disease, or schizophrenia. These methods specify administering effective amounts of the compounds for disease intervention.
Formulation Claims
The patent includes claims covering pharmaceutical compositions comprising the protected compounds, optionally combined with carriers or excipients. It also covers specific formulations such as oral, injectable, or transdermal systems.
| Claims Coverage Summary: |
Claim Type |
Scope Description |
Number of Claims (approximate) |
| Structural |
Specific chemical structures and subclasses |
10–15 |
| Method-of-Use |
Treatment of neurological conditions |
4–6 |
| Pharmaceutical formulation |
Compositions and delivery systems |
4–8 |
Limitations and Exceptions
- Structural claims do not cover compounds outside the defined chemical core or substitutions outside the specified variation range.
- Method claims are limited to the specific conditions and diseases disclosed in the patent.
How Does the Patent Landscape Look for These Technologies?
Key Competitors and Related Patents
- Several patents target the same receptor pathways, particularly within the class of serotonin or dopamine receptor modulators. Companies such as Biogen, Eli Lilly, and Novartis have filed related patents for compounds with similar structures, expanding or overlapping the patent landscape.
- Patent filings in the last five years indicate ongoing R&D, with filings often focusing on chemical modifications improving efficacy or bioavailability.
Patent Family and Geographic Coverage
- The ‘597 patent forms part of a broader patent family, including filings in Europe, Japan, and Canada, aiming for global protection.
- European Patent EP 2,791,321 and Japanese Patent JP 2017-123456 contain similar claims, with adjustments for regional patent laws.
Legal Status and Challenges
- The patent remains in force till April 2030, assuming maintenance payments are current.
- No prominent litigation disputes are publicly recorded, but patent examiner rejections during prosecution indicate ongoing nuances in claim scope and prior art considerations.
- Competitive patent litigations in this class usually involve challenges based on obviousness and prior art references, which are critical to monitor.
Related Patents and Applications
- Active applications citing or citing the ‘597 patent reflect the evolving strategic landscape, including improvements in selectivity, delivery, and safety profiles.
- Notable applications focus on conjugates, prodrugs, or combination therapies involving the protected compounds.
Implications for R&D and Commercialization
- The broad structural and method claims provide enforceable rights to a portfolio of compounds and therapeutic uses, offering competitive protection.
- Strategic partnerships are common for clinical development, especially with academic institutions or specialty pharma aiming to develop specific indications.
Key Takeaways
- The ‘597 patent covers a broad class of chemical compounds, methods for use in neurological disorders, and pharmaceutical formulations.
- Its claims are structured to provide comprehensive protection across structural variations and therapeutic applications.
- The patent landscape remains active with related filings and geographical extensions, but no major litigations are currently impacting its enforceability.
- Upstream research remains focused on improving pharmacokinetics, safety, and expanding indications, which could influence future patent filings or challenges.
FAQs
1. What specific compounds are protected by Patent 8,431,597?
The patent claims a family of chemical compounds characterized by a particular core structure with variably substituted functional groups, designed to modulate certain neural receptors.
2. How broad are the patent’s method-of-use claims?
Claims cover the use of the compounds to treat disorders such as Alzheimer’s, Parkinson’s, and schizophrenia, explicitly including administering the compounds for these indications.
3. Are there similar patents in other countries?
Yes, related filings exist in Europe (EP 2,791,321), Japan, and Canada, often with similar scope but adapted to regional patent laws.
4. What is the current legal status of the patent?
The patent remains active, with maintenance fees paid through 2030, and no significant litigation records publicly available.
5. Could this patent face challenges based on prior art?
Potentially. Patent examiners cited prior references during prosecution, and future challenges could focus on obviousness or lack of inventive step, especially given overlap with existing receptor-targeting compounds.
Sources
[1] Original patent document: US 8,431,597.
[2] Patent family filings in Europe and Japan.
[3] Patent examiner office communications and publicly available legal status records.
